Actively Recruiting
Evaluating SHR-1139 Injection for Adult Ulcerative Pyoderma Gangrenosum Patients Efficacy and Safety Study
Led by Shandong First Medical University · Updated on 2026-09-09
10
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are assessing the effectiveness and safety of SHR-1139 Injection for treating adult patients with ulcerative pyoderma gangrenosum, a condition involving painful skin ulcers. This is a Phase 2 clinical trial sponsored by Shandong First Medical University designed to evaluate this treatment in adults aged 18 years and older who have measurable ulcers requiring systemic therapy. Participants will receive SHR-1139 Injection as the study treatment. The main treatment period includes assessment of the ulcer closure at Week 16, focusing on complete healing of the target ulcer. The trial also monitors partial ulcer closure and safety outcomes up to Week 48, tracking any adverse events during this time. Throughout the study, participants will undergo evaluations of their ulcers at scheduled visits, including measuring the size and healing status of the target pyoderma gangrenosum ulcer. Safety assessments will be conducted regularly to monitor for any side effects. The total study duration extends to June 2028, with a primary outcome measured at Week 16 and follow-up assessments continuing up to Week 48.
CONDITIONS
Brief Title
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
Research Team
F
Furen Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here